Home › NDC Lookup › Ingredients › Pemetrexed Disodium › 70771-1692-01
pemetrexed 500 mg/20mL Injection, Powder, Lyophilized, For Solution — NDC 70771-1692-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

pemetrexed 500 mg/20mL Injection, Powder, Lyophilized, For Solution — NDC 70771-1692-1 (Billing 70771-1692-01)

by Zydus Lifesciences Limited · 1 VIAL in 1 CARTON / 20 mL in 1 VIAL

This is a package of pemetrexed 500 mg/20mL Injection, Powder, Lyophilized, For Solution from Zydus Lifesciences Limited, marketed since May 2022 and currently FDA-listed. It is this product's only package size.

NDC 70771-1692-01
🏷️ FDA NDC (as labeled) 70771-1692-1 billing pads the package segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Pemetrexed Disodium (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jul 29, 2026 — Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials (Shilpa Medicare Limited) · FDA recall D-0764-2026
Class II · Jul 29, 2026 — Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials (Shilpa Medicare Limited) · FDA recall D-0765-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70771-1692-1
Product NDC 70771-1692
11-digit billing NDC 70771169201
RxCUI 1728072, 1728077, 2601728
UNII 2PKU919BA9
Application # ANDA214073
SPL Set ID 6986de29-b077-48ac-ad2b-0cc478f72d89
Established class (EPC) Folate Analog Metabolic Inhibitor
Mechanism of action Folic Acid Metabolism Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-05-26
Route INTRAVENOUS
Dosage form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Substance PEMETREXED DISODIUM
TE code (Orange Book) AP · RLD · RS
Quick answers
  • RxCUI (RxNorm): 1728072
Why two NDCs? The FDA registers this code as 70771-1692-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1692-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Folate Analog Metabolic Inhibitor class.

Pharmacologic class Folate Analog Metabolic Inhibitor
Drug family (ATC) Folic acid analogues
How it works Folic Acid Metabolism Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • It treats non-squamous non-small cell lung cancer, in several situations such as first treatment, maintenance and recurrent disease. It also treats malignant pleural mesothelioma,...
  • It is given as an IV infusion that takes about 10 minutes, on Day 1 of each 21-day cycle. You will also take folic acid daily, get a vitamin B12 shot, and take dexamethasone around...
  • Fatigue, nausea, vomiting, loss of appetite, constipation, diarrhea and mouth sores are common. Low blood counts can also happen, which is why you will have blood tests. Your team...
  • Call for fever or signs of infection, severe skin blistering or peeling, new cough or trouble breathing, or much less urine than usual. Also report redness or blistering where you...
📖 Read our full Pemetrexed Disodium guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70771-1692-01 You're viewing this Main listing 1 VIAL in 1 CARTON / 20 mL in 1 VIAL 2022-05-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Alimta 500 mg/20mL 00002-7623-01 Eli 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 16729-0230-11 Accord 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 25021-0261-50 Sagent 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 31722-0337-31 Camber 1 vial — AP FDA listed —
Pemetrexed disodium 500 mg/20mL 43598-0387-11 Dr. 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 55150-0382-01 Eugia 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 63323-0450-50 Fresenius 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 67184-0504-01 Qilu 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 68001-0536-41 BluePoint 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 68001-0539-41 BluePoint 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 68001-0544-41 BluePoint 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 70069-0835-01 Somerset 1 vial — AP FDA listed —
pemetrexed 500 mg/20mL 70710-1655-01 Zydus 1 vial — AP FDA listed —
pemetrexed 500 mg/20mLthis 70771-1692-01 Zydus 1 vial — AP FDA listed —
Pemetrexed 500 mg/20mL 71288-0146-50 Meitheal 1 vial — AP FDA listed —
Pemetrexed 500 mg/50mL 71288-0167-50 Meitheal 1 vial — AP Discontinued —
Pemetrexed 500 mg/20mL 72338-0101-01 Waverley 1 vial — AP FDA listed —
Pemetrexed 500 mg/50mL 72603-0425-01 NorthStar 1 vial — AP FDA listed —
Pemetrexed Dipotassium 500 mg/20mL 83831-0112-01 Avyxa 1 vial — — FDA listed —
Axtle 500 mg/20mL 83831-0132-01 Avyxa 1 vial — — FDA listed —
Pemetrexed 500 mg/20mL 00781-3519-90 Sandoz 1 vial — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
May 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA214073 (ANDA)
Labeler code70771
First marketedMay 2022
Product typeHuman Prescription Drug
Portfolio720 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel
📄 Package Label / Principal Display Panel 130 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1691-1 Pemetrexed for Injection, USP 100 mg/vial For intravenous use only. Single-Dose Vial Rx only NDC 70771-1691-1 Pemetrexed for Injection, USP 100 mg/vial For intravenous use only. One Single-Dose Vial Carton Rx only NDC 70771-1692-1 Pemetrexed for Injection, USP 500 mg/vial For intravenous use only.

Single-Dose Vial Rx only NDC 70771-1692-1 Pemetrexed for Injection, USP 500 mg/vial For intravenous use only. One Single-Dose Vial Carton Rx only NDC 70771-1693-1 Pemetrexed for Injection, USP 1000 mg/vial For intravenous use only. Single-Dose Vial Rx only NDC 70771-1693-1 Pemetrexed for Injection, USP 1000 mg/vial For intravenous use only.

One Single-Dose Vial Carton Rx only 100 mg vial label 100 mg carton label 500 mg vial label 500 mg carton label 1,000 mg vial label 1,000 mg carton label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Pemetrexed — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Pemetrexed. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$15.9K
Claims incl. refills
11
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$1,441.77
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 70771-1691-01 · Zydus 70771-1693-01 · Zydus →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.